EKITA-DESCARTES Joint Symposium

Humoral alloimmunity

SUNDAY 24 SEPTEMBER 2017 | 09:00-12.50

CHAIRS:  Fritz Diekmann, Berlin, Germany
               Ondrej Viklicky, Prague, Czech Republic

 

09:00-10:40            SESSION 1 

  • Basics of the HLA system
    Caner Süsal, Heidelberg, Germany
  • External validity and variability of solid phase results
    Jürg Steiger, Basel, Switzerland
  • HLA single epitope matching become real?
    Frans Claas, Leiden, The Netherlands
  • Preformed HLA DSAs and outcomes
    Christophe Legendre, Paris, France
  • De novo HLA-DSAs and hard outcomes. How to determine risk (class, number, complement activation?)
    Hans J.W. de Fijter, Leiden, The Netherlands

 

10:40 - 11:00           Break     

 

11:00-12:50            SESSION 2 

  • Alloimmunity trough non-HLA, the human knock out experiment
    Rainer Oberbauer, Vienna, Austria
  • Complement blockade and outcomes – novel approaches beyond eculizumab
    Georg Böhmig, Vienna, Austria
  • Treatment of ABMR features in management biopsies
    Ondrej Viklicky, Praha, Czech Repuplic
  • Underlying mechanisms of spontaneous operational tolerance
    Annick Massart, Brussels, Belgium

 

______________________________________________________________________________________________________

OBJECTIVES | To provide an overview and offer specific solutions for the ‘complicated’/sensitized patient. Solutions range from individualization through omics technologies to bioinformatics approaches.

TARGET AUDIENCE | Transplant surgeons and physicians, nephrologist, immunologists at all stages of training and expertise.

______________________________________________________________________________________________________

EKITA is the kidney section of ESOT and deals with all aspects of renal transplantation. As a European platform, EKITA supports research, education and clinical work in this area. Furthermore, EKITA is highly ambitious in preparing policies and creating transnational interactions to advance renal allografting in all European member states.

GOALS |The main goal of EKITA is to improve quality of life of people with ESRD by advancing all aspects of kidney transplantation.

AIM |The ultimate aim of EKITA is the optimization of renal transplantation trough activities in research, education, clinical collaboration and health policy.